Mast cell activation syndrome (MCAS) is considered a very rare disease and is therefore hardly known by many general practitioners and specialists. Patients are often left without diagnosis and therapy. If patients are lucky enough to be treated by dedicated doctors or therapists, the care often leads to massive billing problems with health insurance companies.
The new disease patterns Long COVID and Post-Vac Syndrome often show a pronounced mast cell activation syndrome and thus bring this disease pattern into the focus of medicine.
In the therapy and disease management of these conditions, the informed patient is becoming increasingly important. More than ever, a partnership of equals between patient and therapist is a prerequisite for successful treatment.